The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
At a glance
- Clinical development success rates for investigational drugs. Nat. Biotechol. 32, 40–51 (2014). et al.
- Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335–339 (2011).
- Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716 (2004). &
- Drug-like properties and the causes of poor solubility and poor permeability. Adv. Drug Delivery Rev. 23, 3–25 (1997).
- The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881–890 (2007).
This paper shows, perhaps for the first time, a link between physicochemical properties, notably lipophilicity and molecular mass, and in vitro promiscuity.
- Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51, 817–834 (2008).
- Physicochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18, 4872–4875 (2008).
From the observation of a link between logP and PSA and toxicology in preclinical in vivo toxicology studies, this study led to what is now known as the 3/75 rule.
- Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 4, 680–686 (2009). , , &
- Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10, 197–208 (2011). , , &
- Strategies to improve the in vivo toxicology outcomes for basic candidate drug molecules. Bioorg. Med. Chem. Lett. 21, 5673–5679 (2011). et al.
- Inflation of correlation in the pursuit of drug-likeness. J. Comput. Aided Mol. Des. 27, 1–13 (2013). &
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419–424 (2012).
Based on an analysis of development failures, this study suggests a set of criteria that a compound should meet to successfully progress through clinical development.
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014). et al.
- Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes. J. Med. Chem. 55, 6455–6466 (2012). et al.
- Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. J. Med. Chem. 56, 9771–9779 (2013). et al.
- A critical assessment of modeling safety-related drug attrition. Med. Chem. Commun. 4, 1058–1065 (2013).
This analysis of the application of physicochemical descriptors to modelling safety attrition suggests that many approaches, including some of those cited here, may not be generally applicable to other data sets.
- The influence of the 'organizational factor' on compound quality in drug discovery. Nat. Rev. Drug Discov. 10, 749–765 (2011). &
- Escape from Flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752–6756 (2009).
This paper suggests that molecules containing a greater degree of saturation, assessed using the fraction of sp3 atoms, may be more likely to progress through various clinical stages.
- The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 49, 2969–2978 (2006).
- Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 49, 3451–3453 (2006). &
- Accurate in silico logP predictions: one can't embrace the unembraceable. QSAR Comb. Sci. 28, 845–849 (2009). et al.
- Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5, 235–248 (2010).
This review analyses the link between lipophilicity and a range of preclinical ADME and toxicology parameters, deriving an optimal range for logD and logP values that are expected to increase the chance of identifying compounds of development candidate quality.
- Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909–922 (2012). et al.
- Defining optimum lipophilicity and molecular weight ranges for drug candidates — molecular weight dependent lower logD limits based on permeability. Bioorg. Med. Chem. Lett. 19, 2844–2851 (2009).
- A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. 17, 1759–1764 (2007). &
- Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci. 31, 315–324 (2006). , ,
- Supplementary information S1 (box) (1.5 MB)
Dataset compilation and statistical analysis